Stocks to Watch
Follow

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Disclaimer
FREE REPORT
Radius Research Radius Research

Radius Research

Loading the Elevenlabs Text to Speech AudioNative Player...

meticulous due diligence. Under the astute leadership of Founder Martin Gagle, the firm has embarked on a mission to demystify the investment landscape, one insightful conversation at a time. Martin hosts a weekly video series, engaging in enlightening discussions with C-suite executives from every corner of the globe, thereby bridging the informational chasm that often exists between companies and potential investors. This initiative not only shines a light on the visions and ventures of seasoned CEOs but also unveils emerging companies poised to make a significant impact in the industry. Radius Research transcends the conventional advisory role by facilitating a platform where ideas exchange hands and trust is the currency. The firm’s offerings are not just robust but come with a stamp of Institutional Quality, ensuring clients are well-equipped with the acumen necessary to navigate the complex financial waters. Through its unwavering commitment to transparency and quality, Radius Research Investments is not just a service provider, but a companion in the investment journey.

Revolve Renewable Power (REVV) 608% Revenue Growth and $2.6 million earnings - CEO Steve Dalton

Radius Research October 30, 2024 7:56 pm

Star Royalties Ltd. is a carbon credit and precious metals royalty and streaming company, with joint venture with Agnico Eagle Mines and Cenovus Energy. The Company innovated the world’s first carbon credit royalties in forestry and regenerative agriculture through its pure-green joint venture, Green Star Royalties Ltd., and offers investors exposure to carbon credit and precious metals prices. 

This video is produced on behalf of the presenting company

STAR ROYALTIES LTD.
@StarRoyalties
$STRR $STRFF $STRR.V

#STRR #starroyalties #carboncredits #naturebasedsolutions #carbonsequestration #preciousmetals
CEO Alex Pernin
VP BD Dmitry Kushnir
  

"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

STAR ROYALTIES LTD.
@StarRoyalties
$STRR $STRFF $STRR.V
#STRR #starroyalties #carboncredits #naturebasedsolutions #carbonsequestration #preciousmetals
STRR Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

Star Royalties Ltd. is a carbon credit and precious metals royalty and streaming company, with joint venture with Agnico Eagle Mines and Cenovus Energy. The Company innovated the world’s first carbon credit royalties in forestry and regenerative agriculture through its pure-green joint venture, Green Star Royalties Ltd., and offers investors exposure to carbon credit and precious metals prices.

This video is produced on behalf of the presenting company

STAR ROYALTIES LTD.
@StarRoyalties
$STRR $STRFF $STRR.V

#STRR #starroyalties #carboncredits #naturebasedsolutions #carbonsequestration #preciousmetals
CEO Alex Pernin
VP BD Dmitry Kushnir


"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

STAR ROYALTIES LTD.
@StarRoyalties
$STRR $STRFF $STRR.V
#STRR #starroyalties #carboncredits #naturebasedsolutions #carbonsequestration #preciousmetals
STRR Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLnljYUZRMmotMnpv

Star Royalties (STRR) CIO Kevin MacLean: Proposed Acquisition of Sabre Gold by Minera Alamos

Radius Research October 29, 2024 3:03 pm

NeuPath Health(NPTH) CEO Joe Walewicz discusses Neupath's large organic and acquisition growth opportunities. Canada's largest provider of pain management The company continues to grow and expand margins through optimization, acquisitions and additional value-added services

CEO Joe Walewicz discusses Neupath's large organic and acquisition growth opportunities. The company continues to grow and expand margins through optimization, acquisitions and additional value-added services.

NeuPath operates a growing network of healthcare clinics and related businesses in Ontario and Alberta focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. The medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. www.neupath.com.

This video is produced on behalf of the presenting company

NEUPATH HEALTH INC.
@NeuPathHealth
$NPTH

#NPTH #neupathhealth #chronicpainmanagement #acupuncturerelief #chronicpainsolutions #healthcare #wellness
CEO Joseph Walewicz
  
  

"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

NEUPATH HEALTH INC.
@NeuPathHealth
$NPTH
#NPTH #neupathhealth #chronicpainmanagement #acupuncturerelief #chronicpainsolutions #healthcare #wellness
NPTH Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

NeuPath Health(NPTH) CEO Joe Walewicz discusses Neupath's large organic and acquisition growth opportunities. Canada's largest provider of pain management The company continues to grow and expand margins through optimization, acquisitions and additional value-added services

CEO Joe Walewicz discusses Neupath's large organic and acquisition growth opportunities. The company continues to grow and expand margins through optimization, acquisitions and additional value-added services.

NeuPath operates a growing network of healthcare clinics and related businesses in Ontario and Alberta focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. The medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. www.neupath.com.

This video is produced on behalf of the presenting company

NEUPATH HEALTH INC.
@NeuPathHealth
$NPTH

#NPTH #neupathhealth #chronicpainmanagement #acupuncturerelief #chronicpainsolutions #healthcare #wellness
CEO Joseph Walewicz



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

NEUPATH HEALTH INC.
@NeuPathHealth
$NPTH
#NPTH #neupathhealth #chronicpainmanagement #acupuncturerelief #chronicpainsolutions #healthcare #wellness
NPTH Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLjFKdm02eXBHYTBF

NeuPath Health (NPTH) Joe Walewicz CEO of Canada's largest chronic pain management services provider

Radius Research October 27, 2024 7:34 pm

Rakovina Therapeutics Inc. has received initial results from the proprietary Deep Docking AI (artificial intelligence) platform.

Rakovina employed the Deep Docking algorithm to evaluate billions of molecular structures to develop a short list of drug candidates that have been optimized to a specific target product profile. A screening effort of this magnitude would not be possible with traditional medicinal chemistry approaches.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.
Cancer Focused Drug Development

This video is produced on behalf of the presenting company.




www.rakovinatherapeutics.com
RAKOVINA THERAPEUTICS INC. 
@rakovina_rkv
$RKV
RKV Stock
#RKV #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

Rakovina Therapeutics Inc. has received initial results from the proprietary Deep Docking AI (artificial intelligence) platform.

Rakovina employed the Deep Docking algorithm to evaluate billions of molecular structures to develop a short list of drug candidates that have been optimized to a specific target product profile. A screening effort of this magnitude would not be possible with traditional medicinal chemistry approaches.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.
Cancer Focused Drug Development

This video is produced on behalf of the presenting company.




www.rakovinatherapeutics.com
RAKOVINA THERAPEUTICS INC.
@rakovina_rkv
$RKV
RKV Stock
#RKV #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLk8xREtzZ3hBaDJv

Rakovina Therapeutics (RKV) Exec Chairman Jeffrey Bacha discusses AI generated drug candidates

Radius Research October 25, 2024 3:39 am

CEO Mark Vanry discusses the innovative growth plan using enhanced recovery techniques to acquire and grow Permian Basin assets.  Wedgemont has just completed a substantial acquisition of additional west-central Texas oil assets which includes 20,000 acres of 37 oil & gas leases, including 111 producing wells.

"Wedgemount Resources is a junior oil & gas company focused on maximizing shareholder value through the acquisition, development and exploitation of natural resource projects in the southern USA.
"

This video is produced on behalf of the presenting company

WEDGEMOUNT RESOURCES CORP.
@wedgemountres
$WDGY $WDGRF

#WDGY #WDGRF #wedgemountresources #oil #oilandgas #energy
CEO Mark Vanry
  
  

"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

WEDGEMOUNT RESOURCES CORP.
@wedgemountres
$WDGY $WDGRF
#WDGY #WDGRF #wedgemountresources #oil #oilandgas #energy
WDGY Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

CEO Mark Vanry discusses the innovative growth plan using enhanced recovery techniques to acquire and grow Permian Basin assets. Wedgemont has just completed a substantial acquisition of additional west-central Texas oil assets which includes 20,000 acres of 37 oil & gas leases, including 111 producing wells.

"Wedgemount Resources is a junior oil & gas company focused on maximizing shareholder value through the acquisition, development and exploitation of natural resource projects in the southern USA.
"

This video is produced on behalf of the presenting company

WEDGEMOUNT RESOURCES CORP.
@wedgemountres
$WDGY $WDGRF

#WDGY #WDGRF #wedgemountresources #oil #oilandgas #energy
CEO Mark Vanry



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

WEDGEMOUNT RESOURCES CORP.
@wedgemountres
$WDGY $WDGRF
#WDGY #WDGRF #wedgemountresources #oil #oilandgas #energy
WDGY Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLkVGSG9feFp2dG5B

Wedgemount Resources (WDGY) CEO Mark Vanry: Innovative Low Cap-Ex & Lo-Risk Growth Model

Radius Research October 13, 2024 2:50 pm

CEO Frank Gleeson and CFO Elizabeth Williams discuss Satellos' novel treatment technology targeting degenerative muscle diseases. Satellos applies its proprietary discovery platform MyoReGenX™ to identify muscle diseases and disorders where muscle tissue is lost or muscle regeneration is defective. The phase 1 clinical trial of SAT-3247 targeting Duchenne Muscular Dystrophy (DMD) has started. 
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX TM , to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com .
Targeting Degenerative Muscle Diseases

This video is produced on behalf of the presenting company.




https://satellos.com/
SATELLOS BIOSCIENCE INC.
"@SatellosBio
"
$MSCL
MSCL Stock
#MSCL #satellosbioscience #duchenne #musculardystrophy #bioscience #disease #muscleregeneration #dmd #stemcell



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

CEO Frank Gleeson and CFO Elizabeth Williams discuss Satellos' novel treatment technology targeting degenerative muscle diseases. Satellos applies its proprietary discovery platform MyoReGenX™ to identify muscle diseases and disorders where muscle tissue is lost or muscle regeneration is defective. The phase 1 clinical trial of SAT-3247 targeting Duchenne Muscular Dystrophy (DMD) has started.
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX TM , to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com .
Targeting Degenerative Muscle Diseases

This video is produced on behalf of the presenting company.




https://satellos.com/
SATELLOS BIOSCIENCE INC.
"@SatellosBio
"
$MSCL
MSCL Stock
#MSCL #satellosbioscience #duchenne #musculardystrophy #bioscience #disease #muscleregeneration #dmd #stemcell



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLkJhT1d3YU1XWmxB

Satellos Bioscience (MSCL) CEO Frank Gleeson: Phase 1 & 2 Milestones for 2024-2025 targeting DMD

Radius Research October 6, 2024 3:56 pm

CEO Corey Giasson and COO Colin Bletsky will be presenting an update and taking questions from the audience.

Mustgrow is an agriculture biotech company developing organic Biocontrol, Soil Amendment and Biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. Mustgrow and its leading global partners -- Janssen PMP (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions' NexusBioAg -- are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 150 independent tests have been completed, validating Mustgrow's safe and effective approach to crop and food protection, and yield and soil improvements. 

This video is produced on behalf of the presenting company

MUSTGROW BIOLOGICS
@MustGrowBio
$MGRO $MGROF $0C0

#MGRO #agriculture #biotech #AG #agritech #sustainability #cropprotection
CEO Corey Giasson
COO Colin Bletsky
  

"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

MUSTGROW BIOLOGICS
@MustGrowBio
$MGRO $MGROF $0C0
#MGRO #agriculture #biotech #AG #agritech #sustainability #cropprotection
MGRO Stock

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

CEO Corey Giasson and COO Colin Bletsky will be presenting an update and taking questions from the audience.

Mustgrow is an agriculture biotech company developing organic Biocontrol, Soil Amendment and Biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world. Mustgrow and its leading global partners -- Janssen PMP (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions' NexusBioAg -- are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 150 independent tests have been completed, validating Mustgrow's safe and effective approach to crop and food protection, and yield and soil improvements.

This video is produced on behalf of the presenting company

MUSTGROW BIOLOGICS
@MustGrowBio
$MGRO $MGROF $0C0

#MGRO #agriculture #biotech #AG #agritech #sustainability #cropprotection
CEO Corey Giasson
COO Colin Bletsky


"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

MUSTGROW BIOLOGICS
@MustGrowBio
$MGRO $MGROF $0C0
#MGRO #agriculture #biotech #AG #agritech #sustainability #cropprotection
MGRO Stock

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLkZVbEV6VDJISFRJ

MustGrow Biologics (MGRO) CEO Corey Giasson give update on commercialization & global partnerships

Radius Research September 29, 2024 3:46 pm

Executive Chairman Jeffery Bacha discusses Rakovina's novel low-cost drug development and partnering strategy targeting DNA-damage response inhibitors.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

This video is produced on behalf of the presenting company

RAKOVINA THERAPEUTICS INC. 
@rakovina_rkv
$RKV

#RKV #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics
Executive Chairman Jeffrey Bacha
  
  

"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

RAKOVINA THERAPEUTICS INC. 
@rakovina_rkv
$RKV
#RKV #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics
RKV Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

Executive Chairman Jeffery Bacha discusses Rakovina's novel low-cost drug development and partnering strategy targeting DNA-damage response inhibitors.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

This video is produced on behalf of the presenting company

RAKOVINA THERAPEUTICS INC.
@rakovina_rkv
$RKV

#RKV #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics
Executive Chairman Jeffrey Bacha



"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

RAKOVINA THERAPEUTICS INC.
@rakovina_rkv
$RKV
#RKV #CancerResearch #DNAResponse #CancerTreatment #OncologyInnovation #Biotech #CancerTherapeutics
RKV Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLkJIQkZNWE91Tjkw

Rakovina Therapeutics (RKV) Exec Chair Jeffery Bacha: A.I. powered drug discovery with out-licensing

Radius Research September 29, 2024 3:46 pm

CEO Doug Childress & Chairman Ralph Garcea discuss the recent acquisition of Claratti and the resulting growth strategy and synergies of the acquisition.

Turnium provides communications and security technologies and services for broadband communications, data centres, and corporate markets.

This video is produced on behalf of the presenting company

TURNIUM TECHNOLOGY GROUP
@Turnium
$TTGI $TTGI.V

#TTGI #turniumtechnology #tech #technology #techstocks #retailtech #SDWAN #internet #wireless #VPNsolutions
CEO Doug Childress
Chairman Ralph Garcea
  

"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A.  -  https://lp.constantcontactpages.com/su/KHhowOK"

TURNIUM TECHNOLOGY GROUP
@Turnium
$TTGI $TTGI.V
#TTGI #turniumtechnology #tech #technology #techstocks #retailtech #SDWAN #internet #wireless #VPNsolutions
TTGI Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

CEO Doug Childress & Chairman Ralph Garcea discuss the recent acquisition of Claratti and the resulting growth strategy and synergies of the acquisition.

Turnium provides communications and security technologies and services for broadband communications, data centres, and corporate markets.

This video is produced on behalf of the presenting company

TURNIUM TECHNOLOGY GROUP
@Turnium
$TTGI $TTGI.V

#TTGI #turniumtechnology #tech #technology #techstocks #retailtech #SDWAN #internet #wireless #VPNsolutions
CEO Doug Childress
Chairman Ralph Garcea


"Please subscribe to The Radius Research Channel if you like these videos and help bring more interviews with high quality companies and CEOs.

Register here to receive my weekly small-cap & venture cap newsletter with live webinar registration for CEO Q&A. - https://lp.constantcontactpages.com/su/KHhowOK"

TURNIUM TECHNOLOGY GROUP
@Turnium
$TTGI $TTGI.V
#TTGI #turniumtechnology #tech #technology #techstocks #retailtech #SDWAN #internet #wireless #VPNsolutions
TTGI Stock








Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLmZYcWFyUFl4WE5F

Turnium Tech (TTGI) CEO Doug Childress & Chairman Ralph Garcea acquisition synergies and growth.

Radius Research September 15, 2024 4:48 pm

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Disclaimer
Advertisement